Why look again at the full-year numbers
Optima Health (LSE:OPT) has made no announcement since its half-year trading update on 20 October, and interim results are due by December. Before those figures arrive, this article examines a detail in the results for the year to 31 March 2026, published on 17 August, that matters for judging margins: a one-off payment from the Department for Work and Pensions.
The settlement
The company had previously won a Court of Appeal challenge over a DWP tender. During the year it reached a full and final settlement and received £4.7m in cash, which it booked as other operating income. No asset had been recognised earlier because the amount and timing were uncertain. That income sits inside adjusted EBITDA, which rose to £20.1m from £17.6m on Revenue up 14.8% at £120.6m, giving an unchanged Margin of 16.7%. The company said adjusted EBITDA was about 10% ahead of previous market expectations, including the settlement.
Stripping it out
Excluding the £4.7m leaves underlying adjusted EBITDA of about £15.4m, a margin of roughly 12.8%. That compares with the reported 16.7% in both years. The company itself gave a split: excluding the settlement, second-half adjusted EBITDA was £9.4m at a 15.4% margin, against £6.0m and 10.1% in the first half. Management attributed the improvement to margin initiatives, despite higher employer National Insurance contributions and Real Living Wage increases.
So the headline margin was flattered, but the second-half run rate was materially better than the first. Statutory operating profit was £4.0m and statutory pre-tax profit £2.5m, after non-recurring items, share-based payments and Amortisation of acquired intangibles. Cash generated from operations rose to £17.3m from £5.4m, which the company said partly reflected the benefit of the settlement income.
The PAM effect
The picture is complicated by the £100m Acquisition of PAM Healthcare, completed on 26 March 2026 and therefore barely in the year's income statement. For calendar 2025, PAM reported unaudited revenue of £66.6m and adjusted EBITDA of £8.2m, a margin of about 12.3%. The company said that the acquisition would weigh on margins in the near term, with improvement expected as integration, efficiencies and contract Maturity come through. It had identified £2.1m of annualised cost synergies by 31 July, against a £5m medium-term target. PAM's brands moved to the Optima Health (LSE:OPT) name on 30 September, which the company said marked completion of the first phase of integration.
Why it matters
Optima's (LSE:OPT) medium-term goal is £40m of adjusted EBITDA on £200m of revenue, a 20% margin. Equally, the 15.4% second-half margin, excluding the settlement, shows the pre-PAM Business was already moving in the right direction. The October update said first-half revenue was about £96m and trading was in line, but gave no profit figure. It did report annualised new business wins of £10.6m in the half, including a programme with HMRC.
Factors to watch and dates
Wage and National Insurance costs affect a clinician-heavy business directly. The Armed Forces Recruitment Service contract, worth up to £210m over seven years, is still in mobilisation and expected to go live in calendar 2027, so its margin contribution is untested. Because the DWP income will not recur, the current year will be compared against a flattered base, which could make reported margin progress look softer than the underlying trend. Net Debt excluding leases fell to £70.4m at 30 September from £94.4m at 31 March, after an open offer funded repayment of a related-party bridge loan. Interim results for the six months to 30 September are expected by December 2026, and should show the first full half including PAM.






Please wait processing your request...